Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Clostridium Botulinum Toxin Type A
Therapeutic Area : Dermatology
Study Phase : Approved FDF
Sponsor : Curi Bio
Deal Size : Undisclosed
Deal Type : Collaboration
Curi Bio, Genetox, DreamCIS Sign MOU for Neuromuscular Junction Model
Details : DreamCIS will support the development of Genetox’s Botaone (clostridium botulinum toxin Type A) for treating glabellar and lateral canthal wrinkles using Curi Bio's neuromuscular junction model.
Product Name : Botaone
Product Type : Protein
Upfront Cash : Undisclosed
February 22, 2024
Lead Product(s) : Clostridium Botulinum Toxin Type A
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Sponsor : Curi Bio
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : MG1113
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Recipient : Green Cross Lab Cell
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : MG1113 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Hemophilia A.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
February 27, 2019
Lead Product(s) : MG1113
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Recipient : Green Cross Lab Cell
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
